Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings that its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution achieves over 99% removal of ultrashort-chain per- and polyfluoroalkyl substances (PFAS), including trifluoroacetic acid (TFA).

TFA is a particularly troublesome contaminant because it is highly persistent, extremely mobile, and resists normal environmental breakdown, experts say. TFA is classified as an ultrashort-chain PFAS. Its small size makes it highly soluble, allowing it to travel long distances in water and even cycle through the atmosphere and rain. Over time, it steadily accumulates in the environment, where it has been shown to harm aquatic plants and ecosystems.

Commonly generated as a byproduct of industrial solvents and chemical processes, TFA's unusual combination of durability and mobility makes it especially difficult to remove once released, placing it among the most difficult of the "forever chemicals" to remove, according to the company.

"Ultrashort-chain PFAS are among the most challenging to capture and remove," said BioLargo Water President Randall Moore. "Our AEC technology has now demonstrated the ability to concentrate and eliminate these compounds with unprecedented efficiency. This further positions BioLargo as a leader in the current and next-generation PFAS treatment industry."

BioLargo is made up of subsidiaries that work in different sectors, a "family of companies," including ONM Environmental, BioLargo Engineering, BioLargo Water, BioLargo Energy Technologies, Clyra Medical Technologies, and the new BioLargo Equipment Solutions & Technologies Inc. (BEST) subsidiary.

'A Game-Changer'

The company's internal testing, conducted alongside third-party laboratories, confirms that AEC consistently removes TFA and other ultrashort-chain PFAS at rates exceeding 99%, without producing harmful byproducts or secondary waste streams, BioLargo said. These results build on BioLargo's previously validated performance with long-chain PFAS such as PFOA and PFOS.

The BioLargo solution facilitates the efficient removal and concentrated collection of PFAS, followed by a proprietary destruction technique. BioLargo's AEC system employs electrostatic forces to selectively attract and isolate charged contaminants from water, enabling scalable, energy-efficient treatment across a wide range of PFAS profiles. The technology is currently being deployed commercially in North America.

"This is a game-changer for communities and any industry grappling with PFAS contamination," said BioLargo Chief Executive Officer Dennis P. Calvert. "We now have solid evidence in hand that our technology can tackle the full spectrum of PFAS compounds — including the ultrashort-chain molecules that others leave behind. We are actively engaged in discussions with potential partners and customers to begin ramping up our commercial activities."

BioLargo has crafted a comprehensive "full-service" water treatment solution that integrates AEC technology with engineering design, installation, PFAS destruction, field testing, and maintenance capabilities, providing clients with a genuine turnkey solution that can generate early revenue for the company in a project's lifecycle.

"While it has taken a long time for BioLargo to achieve success in the water treatment industry, our work has resulted in the company achieving recognition for its role in technology innovation and thought leadership, culminating in our PFAS technology leaders routinely being engaged as expert speakers and trainers for the industry, as well as the appointment of BioLargo's CEO to the U.S. Department of Commerce International Trade Administration's Environmental Technologies Trade Advisory Committee (ETTAC) and as Chairman of its Enabling Innovative Technologies (EIT) subcommittee," Calvert wrote.

For instance, the company exhibited with a booth at WEFTEC 2025, the world's largest water quality event in North America, in Chicago from September 29 to October 1.

PFAS Solution 'Even More Robust'

Chris Temple of The National Investor wrote in light of the company's latest news release, "Just this morning, BioLargo announced that its regimen to remove PFAS 'forever chemicals' from water is even more robust."

The newsletter writer also said he expects to visit the energy division in Oak Ridge, Tennessee, where the company is working on its new battery technology, in a couple of weeks.

The company is also followed by Richard Ryan, analyst with Oak Ridge Financial, who on September 30, 2025 wrote, "Based on our estimates, we believe that the projected success of Pooph, alongside the current valuation of Clyra Medical, provides investors with underlying support and a conservative degree of upside, while the diverse array of technologies within BioLargo's portfolio offers investors an interesting call option,' if you will. We are reaffirming a Buy rating."

The Catalyst: Stricter Federal Regulations

The Trump administration has cut nearly US$15 million in funding for research into PFAS contamination on U.S. farmland, halting studies that health advocates deem crucial for understanding a major source of food contamination, Tom Perkins reported for The Guardian on July 15.

Recent findings have shown that PFAS-laden pesticides and sewage sludge used as fertilizers can contaminate soil, with these chemicals subsequently transferring to crops and nearby water sources. The impact on individuals consuming products from these farms remains uncertain, the author noted.

"We have to do this research and take steps to not just make sure that our food supply is safe, but also ensure our farms and farmers are safe," said Bill Pluecker, a Maine state representative and public policy organizer at the Maine Organic Farmers and Gardeners Association, which has advocated for stricter sludge regulations, according to Perkins.

PFAS includes a group of approximately 15,000 compounds that persist in the environment in the environment and human body and are linked to various severe health issues, including cancer, liver disease, kidney problems, high cholesterol, birth defects, and weakened immunity.

Stricter federal regulations on PFAS are likely to prompt entities such as manufacturers, municipalities, and utilities to manage liability risks more proactively, according to a report by Bloomberg Professional Services in June 2024. "Complying with the rules and cleaning up contamination could require US$300 billion of additional spending by 2040, nearly US$200 billion of which may flow to environmental companies," the report said.

Ownership and Share Structure

About 13.8% of BioLargo is owned by insiders and management, according to Refinitiv. They include Chief Science Officer Kenneth Code with 8.19%, CEO Calvert with 3.25%, and Director Jack Strommen with 1.58%.

About 0.04% is held by the institution First American Trust, Refinitiv said.

The rest, about 85%, is retail.

Its market cap is US$52.35 million, with about 308.99 million shares outstanding and about 266.36 million free-floating. It trades in a 52-week range of US$0.32 and US$0.14.